Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.59 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.56 |
| ▸ | PI4KA | P42356 | 3/20 | 0.55 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.55 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.55 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | AHCY | P23526 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6029046 | 0.87 | ADORA2A (0.63) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL6029347 | 0.81 | ADCY5 (0.65) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL9204975 | 0.80 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL4811419 | 0.79 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| Hydrochloric Acid SCHEMBL10339774 | 0.78 | ADORA2A (0.62) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL11222112 | 0.78 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL14355770 | 0.78 | ADCY5 (0.57) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL19841 | 0.77 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL6029039 | 0.77 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL2638103 | 0.77 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BADCY5PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478653-B1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-6995143-B2 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2006-02-07 | — | — | US | disclosed |
| US-20030212011-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212011-A1 | Macrolides with antibacterial activity | MRPL21, RPS21, MRPS18A | ADORA2A 4653/4885ADORA1 3267/4885ADORA2B 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.